Initial Experience With A New Endoscopic Ultrasound Electric Core Biopsy Device

Aims Endoscopic ultrasound guided biopsy via FNB/FNA is currently the standard method to sample tumors in mediastinum and abdomen but a histological diagnosis is not always possible. Recently, a new EUS-guided core biopsy (EUS-CB) device became available with the intent of improving the overall sample quality and rate of histological diagnoses. The aim of this study was to evaluate its performance in a real-world setting across different centers.

Methods This is a retrospective study of patients who underwent EUS-CB at five academic centers. Biopsies were obtained with a flexible 17G electric high-speed spinning device that obtains core specimens via controlled drilling of the target lesion. All patients provided written informed consent and were observed in the hospital after the procedure.

Results A total of 28 patients underwent EUSC-CB. The mean age of the patients was 65 years and 10 were males. The most common tumor sites were pancreas, retroperitoneum and stomach. Transmural biopsies were performed in 24 patients (trans-gastric 12, trans-duodenal 11, trans-esophageal 1). Tumor size ranged from 1-13 cm (mean 5). In 22 (79%) patients the first and only pass with EUS-CB was enough to yield diagnostic tissue; in the remaining 6 pts, diagnosis was made with same-session 22G FNB samples. The only immediate adverse event was mild bleeding in 2 patients that was successfully treated endoscopically. No delayed adverse events were documented.

Conclusions The overall initial experience with this new EUS-CB device was positive. Our findings suggest that the device is effective and safe. Its effectiveness at obtaining adequate tissue with one pass could potentially shorten the overall duration of the procedure. Prospective studies comparing it to FNA/FNB needles will be required to further assess performance and safety.

Publikationsverlauf

Artikel online veröffentlicht:
27. März 2025